Navamepent

Navamepent
Clinical data
Other names	RX-10045
Identifiers
	IUPAC name propan-2-yl (5S,8E,10E,12R)-5,12-dihydroxypentadeca-8,10-dien-6,14-diynoate;
CAS Number	1251537-11-7;
PubChem CID	46926878;
IUPHAR/BPS	9463;
ChemSpider	57490355;
UNII	Q7789B8MWM;
ChEMBL	ChEMBL5314965;
Chemical and physical data
Formula	C18H24O4
Molar mass	304.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)OC(=O)CCC[C@@H](C#C/C=C/C=C/[C@@H](CC#C)O)O;
	InChI InChI=1S/C18H24O4/c1-4-10-16(19)11-7-5-6-8-12-17(20)13-9-14-18(21)22-15(2)3/h1,5-7,11,15-17,19-20H,9-10,13-14H2,2-3H3/b6-5+,11-7+/t16-,17-/m1/s1; Key:ZVOCIIHCJJEFRQ-BHXBHYJPSA-N;

Navamepent (RX-10045) is a synthetic analogue^[1] of the endogenous fatty acid resolvin E1, a member of the specialized pro-resolving mediators. Navamepent is presumed to act as an agonist of the CMKLR1 receptor in a manner similar to resolvin E1.

It was developed as a topical ophthalmic formulation to promote recovery from eye inflammation and advanced to Phase II clinical trials, but was not pursued further.^[2]^[3]^[4]

References

^ WO 2010120719, Gjorstrup P, Schwartz CE, "Compositions and methods for the treatment of inflammation", published 21 October 2010, assigned to Resolvyx Pharmaceuticals, Inc.
^ Torricelli AA, Santhanam A, Agrawal V, Wilson SE (2014). "Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK". Molecular Vision. 20: 1710–1716. PMC 4279593. PMID 25558174.
^ Hesselink JM, Chiosi F, Costagliola C (2016). "Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold?". Drug Design, Development and Therapy. 10: 3133–3141. doi:10.2147/DDDT.S112389. PMC 5045908. PMID 27729772.
^ Serhan CN (April 2017). "Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms". FASEB Journal. 31 (4): 1273–1288. doi:10.1096/fj.201601222R. PMC 5349794. PMID 28087575.

[1] WO 2010120719, Gjorstrup P, Schwartz CE, "Compositions and methods for the treatment of inflammation", published 21 October 2010, assigned to Resolvyx Pharmaceuticals, Inc.

[2] Torricelli AA, Santhanam A, Agrawal V, Wilson SE (2014). "Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK". Molecular Vision. 20: 1710–1716. PMC 4279593. PMID 25558174.

[3] Hesselink JM, Chiosi F, Costagliola C (2016). "Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold?". Drug Design, Development and Therapy. 10: 3133–3141. doi:10.2147/DDDT.S112389. PMC 5045908. PMID 27729772.

[4] Serhan CN (April 2017). "Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms". FASEB Journal. 31 (4): 1273–1288. doi:10.1096/fj.201601222R. PMC 5349794. PMID 28087575.

[1]

[2]

[3]

[4]